Search - tctmd.com

Displaying 21 - 38 of 38

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2021

Shelley Wood

July 05, 2021

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

News Daily News

Statins Not Linked to Dementia or Memory Changes: ASPREE

Michael O'Riordan

June 21, 2021

News Daily News

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Michael O'Riordan

June 18, 2021

News Conference News EAS 2021

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

Michael O'Riordan

June 07, 2021

News Conference News EAS 2021

Lp(a) Not Associated With Ongoing Aortic Valve Calcification

Michael O'Riordan

June 04, 2021

News Daily News

It Pays to Reward Doctors for Risk-Stratifying Patients, Early Data Hint

L.A. McKeown

June 04, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Daily News

AHA: Physical Activity Should First-line Therapy as BP, LDL Tick Upwards

Michael O'Riordan

June 02, 2021

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Conference News EHRA 2021

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

Todd Neale

April 26, 2021

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

Shelley Wood

April 02, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Daily News

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Michael O'Riordan

January 14, 2021

Advertisement

TCTMD’s Top 10 Most Popular Stories for June 2021

OMT Boosts Survival in Revascularized Patients at 10 Years

Less Cancer Among HF Patients Taking Statins, Registry Shows

Statins Not Linked to Dementia or Memory Changes: ASPREE

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

Lp(a) Not Associated With Ongoing Aortic Valve Calcification

It Pays to Reward Doctors for Risk-Stratifying Patients, Early Data Hint

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

AHA: Physical Activity Should First-line Therapy as BP, LDL Tick Upwards

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

TCTMD’s Top 10 Most Popular Stories for March 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Approves Evinacumab for Rare Homozygous FH

CAC Screening Cost-effective for Statin Decisions in Hereditary CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content